Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis
March 17, 2014
- National University Hospitals to Disclose Funding from Autumn, but with Company Names Withheld
March 11, 2014
- JAMS’s Newly Revised COI Management Guidelines Impose Stricter Rules
February 28, 2014
- Japanese Cardiologist Raises Statistical Concerns over CASE-J Study in US Journal
February 28, 2014
- NCNP to Begin Investigator-Initiated Trial of Multiple Sclerosis Treatment
February 28, 2014
- Japan Diabetes Society Crosses Out SMART Study from Its Guidelines
February 25, 2014
- US Journal Officially Announces Retraction of SMART Study
February 24, 2014
- Japan Hypertension Society Halts Support for Maker-Linked Seminars, but Gives Leeway for Luncheons
February 18, 2014
- University of Tokyo Hospital Allegedly Gave Patient Questionnaire Results on SIGN Trial to Novartis without Consent
February 13, 2014
- SMART Study Sub-Analysis Paper to Be Retracted from JSH Journal
February 12, 2014
- University of Tokyo Besieged with Medical, Pharma Research Woes, School’s Credibility at Stake
February 7, 2014
- JAS Sees “No Need” to Change Its Guidelines in Response to 2013 ACC/AHA Guidelines for the Prevention of ASCVD
February 5, 2014
- SGLT-2 Inhibitors “Suited to Patients with Tendency to Obesity”: Prof. Kadowaki of Univ. of Tokyo
February 4, 2014
- Japan Hypertension Society Won’t Co-Sponsor or Support Drug Maker-Linked Seminars for Now
January 29, 2014
- JCS’s 2013 Guidelines for Treatment of AF Recommend Dabigatran and Apixaban in Moderate-Risk Patients
January 29, 2014
- SMART Study Should Be Removed from CKD Guidelines: Society Panel Chair
January 22, 2014
- SMART Study Retracted from US Journal, Chief Investigator to Resign as Hospital Director
January 22, 2014
- AJMC Announces Guidelines for COI Management at Research and Medical Institutions
December 25, 2013
- Chiba University Finds No Proof of Manipulation in Diovan Study
December 18, 2013
- Nagoya University Denies Diovan Clinical Data Manipulated
December 16, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…